TrialJAMA oncology2018

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Naoko Matsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.